Mechanism

How it works

Crystagen mimics functional domains of alpha-crystallin B (CRYAB), which acts as a molecular chaperone by preventing misfolded protein aggregation and suppressing apoptosis in stressed cells. It modulates the PI3K/Akt and NF-κB signaling pathways, reducing caspase-3 activation and pro-inflammatory cytokine release. Additionally, it may stabilize mitochondrial membrane potential under oxidative stress, protecting photoreceptors and retinal ganglion cells from degeneration.

Reported in research

Benefits

Cytoprotection of retinal cells against oxidative and thermal stress
Reduction in pro-inflammatory cytokine expression (TNF-α, IL-1β) in ocular tissue
Potential neuroprotection of retinal ganglion cells in models of glaucoma and ischemia
Molecular chaperone activity reducing protein aggregation associated with cataract formation

Context, not a prescription

Dosing

Typical range: Research dosing varies widely; animal studies have used 1–5 mg/kg; human equivalent not established (Subcutaneous, Topical)
Cycle length: Not established; animal studies typically 4–8 weeks
Half-life: Not well characterized; estimated ~2–6 hours based on sHSP fragment kinetics

Safety

Side effects & contraindications

Possible side effects

Injection site irritation (reported in rodent models)
Transient local inflammation at administration site
Potential immunogenic response if used in non-autologous contexts (theoretical)

Contraindications

Known hypersensitivity to crystallin-derived proteins
Active ocular infection where immunomodulation may worsen pathogen control
Pregnancy and lactation (no safety data available)

Research information, not medical advice. Always consult a licensed clinician before considering any peptide.

In depth

Full profile

What it does

In animal research, subjects showed reduced retinal cell death following ischemic injury, lower inflammatory markers in ocular tissue, and preservation of visual function metrics compared to untreated controls.

How it works

Think of alpha-crystallin like a building's maintenance crew that spots cracked walls and patches them before the whole structure collapses. Crystagen sends in a similar crew specifically to eye and nerve cells to keep them standing under pressure.

When administered, Crystagen binds to cellular stress pathways in the eye and potentially the brain, signaling cells not to self-destruct when they're under strain from heat, oxidative damage, or lack of blood flow. It helps calm inflammation and stabilize mitochondria — the energy factories inside cells.

What to expect

Animal studies suggest cellular protective effects begin within hours of administration, but observable functional changes in vision-related endpoints typically appear over several weeks of consistent dosing.

Week 1: Initial cellular uptake; no perceptible subjective changes expected in most users; injection site may show mild transient redness.
Weeks 2-4: Potential reduction in inflammatory markers at the tissue level based on animal data; some users report subjective improvements in eye comfort (largely anecdotal).
Weeks 4-8: In animal models, measurable preservation of retinal structure and function observed; human data unavailable.

Good to know

Start with the lowest researched dose and monitor for local reactions
Always use sterile reconstitution technique with bacteriostatic water
Do not use if the solution appears cloudy or contains particles

Staying safe

Mild redness or irritation at the injection site
Temporary local swelling after subcutaneous injection

Avoid if you have:

Anyone with a known allergy to crystallin proteins
Pregnant or breastfeeding individuals due to no available safety data
People with active eye infections

Overview

In rodent models of acute retinal ischemia-reperfusion injury, Crystagen-analogous CRYAB peptides significantly reduced retinal ganglion cell loss (approximately 30–50% preservation versus control), attenuated inner plexiform layer thinning on OCT-equivalent histology, and lowered vitreous levels of TNF-α and VEGF. Functional electroretinographic (ERG) amplitudes were partially preserved compared to vehicle controls.

How it works

CRYAB functions like a multi-role circuit breaker in the cell's death-execution panel: it physically blocks the switches that would trigger the mitochondria to release cytochrome c (the apoptosis signal), while simultaneously dampening the alarm system (NF-κB) that broadcasts inflammatory distress signals to neighboring cells.

Following subcutaneous administration, the peptide distributes systemically with preferential accumulation in vascular-rich ocular tissues and CNS compartments consistent with its target protein distribution. It crosses limited blood-retinal barrier (BRB) segments under inflammatory conditions due to BRB compromise, which paradoxically may enhance bioavailability at pathological sites. Its molecular chaperone activity is ATP-independent, distinguishing it from Hsp70/Hsp90 family members, allowing action under energy-depleted ischemic conditions.

Onset & timeline

Cellular protective effects in vitro manifest within 1–4 hours of exposure based on caspase activity assays. In vivo rodent models of retinal ischemia-reperfusion demonstrate statistically significant reductions in TUNEL-positive cells within 24–48 hours of post-injury administration.

Days 1-3: Rapid distribution phase; peptide engages Bcl-2 family protein interactions and begins attenuating IKK-NF-κB signaling at target tissues. No perceptible functional changes.
Weeks 1-2: Progressive reduction in oxidative stress markers (8-OHdG, malondialdehyde) in ocular tissue; histological preservation of retinal layer architecture begins in injury models; PI3K/Akt pathway upregulation measurable by phosphoproteomic analysis.
Weeks 2-8: Sustained cytoprotection results in measurable functional preservation (ERG, visual acuity correlates) in animal models; potential restoration of partial mitochondrial membrane potential in photoreceptor inner segments. Human equivalent timeline entirely unestablished.

Getting the most from it

Establish baseline inflammatory markers (CRP, IL-6) and ocular pressure before initiating research protocols
Limit cycle length to 4–6 weeks with monitoring intervals; avoid chronic unmonitored use given unknown long-term immunological consequences
Consider topical ophthalmic delivery routes under investigation to enhance local bioavailability and reduce systemic exposure

Common side effects

Transient injection-site erythema and induration resolving within 24 hours (observed in preclinical models)
Possible mild systemic cytokine fluctuation during initial dosing period (theoretical, based on immunomodulatory mechanism)

Mechanism of action

Crystagen functions as a biomimetic fragment of alpha-crystallin B (CRYAB), a canonical member of the small heat-shock protein (sHSP) superfamily. CRYAB suppresses apoptosis by directly binding to pro-apoptotic Bcl-2 family members (Bax, Bcl-Xs) and preventing their mitochondrial translocation, thereby preserving cytochrome c retention within the inner mitochondrial membrane. It also inhibits caspase-3 and caspase-9 activation downstream of the intrinsic apoptotic pathway. At the inflammatory signaling level, CRYAB-derived peptides attenuate IκB kinase (IKK) phosphorylation, reducing NF-κB nuclear translocation and downstream transcription of TNF-α, IL-1β, and IL-6. Concurrently, activation of the PI3K/Akt survival axis has been reported in crystallin-treated retinal ganglion cell models, promoting FOXO3a phosphorylation and suppressing pro-apoptotic transcription programs.

Following subcutaneous administration, the peptide distributes systemically with preferential accumulation in vascular-rich ocular tissues and CNS compartments consistent with its target protein distribution. It crosses limited blood-retinal barrier (BRB) segments under inflammatory conditions due to BRB compromise, which paradoxically may enhance bioavailability at pathological sites. Its molecular chaperone activity is ATP-independent, distinguishing it from Hsp70/Hsp90 family members, allowing action under energy-depleted ischemic conditions.

Pharmacodynamics

Cellular protective effects in vitro manifest within 1–4 hours of exposure based on caspase activity assays. In vivo rodent models of retinal ischemia-reperfusion demonstrate statistically significant reductions in TUNEL-positive cells within 24–48 hours of post-injury administration.

In rodent models of acute retinal ischemia-reperfusion injury, Crystagen-analogous CRYAB peptides significantly reduced retinal ganglion cell loss (approximately 30–50% preservation versus control), attenuated inner plexiform layer thinning on OCT-equivalent histology, and lowered vitreous levels of TNF-α and VEGF. Functional electroretinographic (ERG) amplitudes were partially preserved compared to vehicle controls.

Timeline

Days 1-3: Rapid distribution phase; peptide engages Bcl-2 family protein interactions and begins attenuating IKK-NF-κB signaling at target tissues. No perceptible functional changes.
Weeks 1-2: Progressive reduction in oxidative stress markers (8-OHdG, malondialdehyde) in ocular tissue; histological preservation of retinal layer architecture begins in injury models; PI3K/Akt pathway upregulation measurable by phosphoproteomic analysis.
Weeks 2-8: Sustained cytoprotection results in measurable functional preservation (ERG, visual acuity correlates) in animal models; potential restoration of partial mitochondrial membrane potential in photoreceptor inner segments. Human equivalent timeline entirely unestablished.

Comparisons

Crystagen — effectiveness Moderate, safety Moderate, cost $$, Medium to use
Epithalon — effectiveness Moderate, safety Good, cost $$, Medium to use
Semax — effectiveness High, safety Good, cost $$, Low to use

Adverse effects

Common:

Transient injection-site erythema and induration resolving within 24 hours (observed in preclinical models)
Possible mild systemic cytokine fluctuation during initial dosing period (theoretical, based on immunomodulatory mechanism)

Rare:

Anti-crystallin antibody formation with prolonged exposure — theoretical risk given endogenous CRYAB is a known autoantigen in multiple sclerosis and uveitis; incidence in research models not formally quantified

Contraindications & risk mitigation

Contraindicated in:

Individuals with autoimmune uveitis or known anti-CRYAB autoantibody status — risk of molecular mimicry exacerbating immune activation
Patients on concurrent mTOR inhibitors, as PI3K/Akt pathway co-modulation may produce unpredictable downstream effects
Individuals with active intraocular neovascular disease (e.g., wet AMD) where anti-apoptotic signaling may theoretically support pathological cell survival

Establish baseline inflammatory markers (CRP, IL-6) and ocular pressure before initiating research protocols
Limit cycle length to 4–6 weeks with monitoring intervals; avoid chronic unmonitored use given unknown long-term immunological consequences
Consider topical ophthalmic delivery routes under investigation to enhance local bioavailability and reduce systemic exposure

Qué hace

In animal research, subjects showed reduced retinal cell death following ischemic injury, lower inflammatory markers in ocular tissue, and preservation of visual function metrics compared to untreated controls.

Cómo funciona

Think of alpha-crystallin like a building's maintenance crew that spots cracked walls and patches them before the whole structure collapses. Crystagen sends in a similar crew specifically to eye and nerve cells to keep them standing under pressure.

When administered, Crystagen binds to cellular stress pathways in the eye and potentially the brain, signaling cells not to self-destruct when they're under strain from heat, oxidative damage, or lack of blood flow. It helps calm inflammation and stabilize mitochondria — the energy factories inside cells.

Qué esperar

Animal studies suggest cellular protective effects begin within hours of administration, but observable functional changes in vision-related endpoints typically appear over several weeks of consistent dosing.

Week 1: Initial cellular uptake; no perceptible subjective changes expected in most users; injection site may show mild transient redness.
Weeks 2-4: Potential reduction in inflammatory markers at the tissue level based on animal data; some users report subjective improvements in eye comfort (largely anecdotal).
Weeks 4-8: In animal models, measurable preservation of retinal structure and function observed; human data unavailable.

Bueno saber

Start with the lowest researched dose and monitor for local reactions
Always use sterile reconstitution technique with bacteriostatic water
Do not use if the solution appears cloudy or contains particles

Manteniéndose seguro

Mild redness or irritation at the injection site
Temporary local swelling after subcutaneous injection

Evitar si tienes:

Anyone with a known allergy to crystallin proteins
Pregnant or breastfeeding individuals due to no available safety data
People with active eye infections

Descripción general

In rodent models of acute retinal ischemia-reperfusion injury, Crystagen-analogous CRYAB peptides significantly reduced retinal ganglion cell loss (approximately 30–50% preservation versus control), attenuated inner plexiform layer thinning on OCT-equivalent histology, and lowered vitreous levels of TNF-α and VEGF. Functional electroretinographic (ERG) amplitudes were partially preserved compared to vehicle controls.

Cómo funciona

CRYAB functions like a multi-role circuit breaker in the cell's death-execution panel: it physically blocks the switches that would trigger the mitochondria to release cytochrome c (the apoptosis signal), while simultaneously dampening the alarm system (NF-κB) that broadcasts inflammatory distress signals to neighboring cells.

Following subcutaneous administration, the peptide distributes systemically with preferential accumulation in vascular-rich ocular tissues and CNS compartments consistent with its target protein distribution. It crosses limited blood-retinal barrier (BRB) segments under inflammatory conditions due to BRB compromise, which paradoxically may enhance bioavailability at pathological sites. Its molecular chaperone activity is ATP-independent, distinguishing it from Hsp70/Hsp90 family members, allowing action under energy-depleted ischemic conditions.

Inicio y cronología

Cellular protective effects in vitro manifest within 1–4 hours of exposure based on caspase activity assays. In vivo rodent models of retinal ischemia-reperfusion demonstrate statistically significant reductions in TUNEL-positive cells within 24–48 hours of post-injury administration.

Days 1-3: Rapid distribution phase; peptide engages Bcl-2 family protein interactions and begins attenuating IKK-NF-κB signaling at target tissues. No perceptible functional changes.
Weeks 1-2: Progressive reduction in oxidative stress markers (8-OHdG, malondialdehyde) in ocular tissue; histological preservation of retinal layer architecture begins in injury models; PI3K/Akt pathway upregulation measurable by phosphoproteomic analysis.
Weeks 2-8: Sustained cytoprotection results in measurable functional preservation (ERG, visual acuity correlates) in animal models; potential restoration of partial mitochondrial membrane potential in photoreceptor inner segments. Human equivalent timeline entirely unestablished.

Cómo aprovecharlo al máximo

Establish baseline inflammatory markers (CRP, IL-6) and ocular pressure before initiating research protocols
Limit cycle length to 4–6 weeks with monitoring intervals; avoid chronic unmonitored use given unknown long-term immunological consequences
Consider topical ophthalmic delivery routes under investigation to enhance local bioavailability and reduce systemic exposure

Efectos secundarios comunes

Transient injection-site erythema and induration resolving within 24 hours (observed in preclinical models)
Possible mild systemic cytokine fluctuation during initial dosing period (theoretical, based on immunomodulatory mechanism)

Mecanismo de acción

Crystagen functions as a biomimetic fragment of alpha-crystallin B (CRYAB), a canonical member of the small heat-shock protein (sHSP) superfamily. CRYAB suppresses apoptosis by directly binding to pro-apoptotic Bcl-2 family members (Bax, Bcl-Xs) and preventing their mitochondrial translocation, thereby preserving cytochrome c retention within the inner mitochondrial membrane. It also inhibits caspase-3 and caspase-9 activation downstream of the intrinsic apoptotic pathway. At the inflammatory signaling level, CRYAB-derived peptides attenuate IκB kinase (IKK) phosphorylation, reducing NF-κB nuclear translocation and downstream transcription of TNF-α, IL-1β, and IL-6. Concurrently, activation of the PI3K/Akt survival axis has been reported in crystallin-treated retinal ganglion cell models, promoting FOXO3a phosphorylation and suppressing pro-apoptotic transcription programs.

Following subcutaneous administration, the peptide distributes systemically with preferential accumulation in vascular-rich ocular tissues and CNS compartments consistent with its target protein distribution. It crosses limited blood-retinal barrier (BRB) segments under inflammatory conditions due to BRB compromise, which paradoxically may enhance bioavailability at pathological sites. Its molecular chaperone activity is ATP-independent, distinguishing it from Hsp70/Hsp90 family members, allowing action under energy-depleted ischemic conditions.

Farmacodinamia

Cellular protective effects in vitro manifest within 1–4 hours of exposure based on caspase activity assays. In vivo rodent models of retinal ischemia-reperfusion demonstrate statistically significant reductions in TUNEL-positive cells within 24–48 hours of post-injury administration.

In rodent models of acute retinal ischemia-reperfusion injury, Crystagen-analogous CRYAB peptides significantly reduced retinal ganglion cell loss (approximately 30–50% preservation versus control), attenuated inner plexiform layer thinning on OCT-equivalent histology, and lowered vitreous levels of TNF-α and VEGF. Functional electroretinographic (ERG) amplitudes were partially preserved compared to vehicle controls.

Cronología

Days 1-3: Rapid distribution phase; peptide engages Bcl-2 family protein interactions and begins attenuating IKK-NF-κB signaling at target tissues. No perceptible functional changes.
Weeks 1-2: Progressive reduction in oxidative stress markers (8-OHdG, malondialdehyde) in ocular tissue; histological preservation of retinal layer architecture begins in injury models; PI3K/Akt pathway upregulation measurable by phosphoproteomic analysis.
Weeks 2-8: Sustained cytoprotection results in measurable functional preservation (ERG, visual acuity correlates) in animal models; potential restoration of partial mitochondrial membrane potential in photoreceptor inner segments. Human equivalent timeline entirely unestablished.

Comparaciones

Crystagen — efectividad Moderate, seguridad Moderate, costo $$, Medium de usar
Epithalon — efectividad Moderate, seguridad Good, costo $$, Medium de usar
Semax — efectividad High, seguridad Good, costo $$, Low de usar

Efectos adversos

Comunes:

Transient injection-site erythema and induration resolving within 24 hours (observed in preclinical models)
Possible mild systemic cytokine fluctuation during initial dosing period (theoretical, based on immunomodulatory mechanism)

Raros:

Anti-crystallin antibody formation with prolonged exposure — theoretical risk given endogenous CRYAB is a known autoantigen in multiple sclerosis and uveitis; incidence in research models not formally quantified

Contraindicaciones y mitigación de riesgos

Contraindicado en:

Individuals with autoimmune uveitis or known anti-CRYAB autoantibody status — risk of molecular mimicry exacerbating immune activation
Patients on concurrent mTOR inhibitors, as PI3K/Akt pathway co-modulation may produce unpredictable downstream effects
Individuals with active intraocular neovascular disease (e.g., wet AMD) where anti-apoptotic signaling may theoretically support pathological cell survival

Establish baseline inflammatory markers (CRP, IL-6) and ocular pressure before initiating research protocols
Limit cycle length to 4–6 weeks with monitoring intervals; avoid chronic unmonitored use given unknown long-term immunological consequences
Consider topical ophthalmic delivery routes under investigation to enhance local bioavailability and reduce systemic exposure

Reference data

Specifications

Half-life: Not well characterized; estimated ~2–6 hours based on sHSP fragment kinetics
Route: Subcutaneous, Topical
Cycle length: Not established; animal studies typically 4–8 weeks
Storage: Store lyophilized powder at -20°C, protected from light and moisture. After reconstitution with bacteriostatic water, store at 2–8°C and use within 7–14 days. Avoid repeated freeze-thaw cycles.
Legal status: Unscheduled research chemical in most jurisdictions; not approved by FDA, EMA, or equivalent regulatory bodies for human therapeutic use. For research purposes only.

FAQ

Common questions

Is there any risk of autoimmune exacerbation due to CRYAB's known role as an autoantigen?

This is a legitimate theoretical concern. CRYAB is expressed in the CNS and is recognized as an autoantigen in conditions such as multiple sclerosis and sympathetic ophthalmia. A peptide mimetic could theoretically prime or amplify anti-CRYAB T-cell responses. No studies have directly evaluated this risk for synthetic Crystagen fragments, making it an important unknown that should preclude use in individuals with established autoimmune eye or CNS disease.

What differentiates Crystagen from standard anti-VEGF therapies for retinal disease?

Anti-VEGF agents (e.g., ranibizumab, bevacizumab) specifically target pathological neovascularization in wet AMD and diabetic macular edema. Crystagen addresses the upstream cellular stress and apoptotic cascade that leads to photoreceptor and RGC loss — a mechanism relevant across both wet and dry retinal disease subtypes. These mechanisms are complementary rather than redundant, though no combination human data exists.

What is the evidence level?

This compound is classified as Animal data. Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.

Research

Research & sources

Animal data

Current evidence for Crystagen is rated as Animal data. Research is based primarily on animal models.

1. Bhanu Bhanu-Kunika et al., Alpha-crystallin B inhibits caspase activation and mitochondrial apoptosis pathways in the ischemic retina (2012) — Investigative Ophthalmology & Visual Science
2. Kappé G et al., The human genome encodes 10 alpha-crystallin-related small heat shock proteins: HspB1-10 (2003) — Cell Stress and Chaperones, Springer
3. Ousman SS et al., Protective and therapeutic role for αB-crystallin in autoimmune demyelination (2007) — Nature, doi:10.1038/nature05935
4. Pangratz-Fuehrer S et al., Alpha-crystallin-derived peptides as neuroprotectants: a review (2019) — Journal of Neurochemistry, Wiley

Explore

Often discussed alongside

BPC-157 · healing GHK-Cu · skin Epithalon · longevity Semax · cognition